Reports Q2 revenue $28.3M, consensus $18.7M. Cash, cash equivalents and restricted cash were $253.4 million as of June 30, 2025, and $293.9 million on December 31, 2024. Based on the current pipeline and programs, the cash runway remains extended into 2028. “The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,” said Joseph Payne, President & CEO of Arcturus Therapeutics (ARCT). “We are especially pleased with the recent proof-of-concept in our liver platform based on the positive ARCT-810 interim Phase 2 data and look forward to sharing two cohorts of Phase 2 CF data in September.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Is ARCT a Buy, Before Earnings?
- Private Markets: Canva draws attention as IPO candidate following Figma debut
- Arcturus Therapeutics: Strategic Focus Beyond mRNA Vaccines Drives Buy Rating
- Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating
- 3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts